Selected article for: "immune system and molecular pattern"
Author: Chen, Ruochan; Huang, Yan; Quan, Jun; Liu, Jiao; Wang, Haichao; Billiar, Timothy R.; Lotze, Michael T.; Zeh, Herbert J.; Kang, Rui; Tang, Daolin
Title: HMGB1 as a potential biomarker and therapeutic target for severe COVID-19
  • Cord-id: z6wdhijv
  • Document date: 2020_12_7
    • ID: z6wdhijv
    Snippet: COVID-19 has attracted global attention due to its rapid spread around the world with substantial morbidity and associated mortality. Severe COVID-19 can be complicated by the acute respiratory distress syndrome, sepsis and septic shock leading to death. These complications are thought to result from an overactivation of the immune system, leading to a cytokine storm syndrome associated with multiple organ failure. Here, we report that high mobility group box 1 (HMGB1), a prototypical damage-ass
    Document: COVID-19 has attracted global attention due to its rapid spread around the world with substantial morbidity and associated mortality. Severe COVID-19 can be complicated by the acute respiratory distress syndrome, sepsis and septic shock leading to death. These complications are thought to result from an overactivation of the immune system, leading to a cytokine storm syndrome associated with multiple organ failure. Here, we report that high mobility group box 1 (HMGB1), a prototypical damage-associated molecular pattern (DAMP) and a central mediator of lethal inflammation, could be a potential target for innovative therapeutic strategies for COVID-19. Serum HMGB1 in severe COVID-19 patients is elevated (189.40 ± 140.88 ng/ml). Exogenous HMGB1 induces the expression of SARS-CoV-2 entry receptor ACE2 in alveolar epithelial cells in an AGER-dependent manner. Importantly, genetic (using AGER siRNA) or pharmacological (using glycyrrhizin, chloroquine, hydroxychloroquine, and FPS-ZM1) inhibition of the HMGB1-AGER pathway blocks ACE2 expression. Thus, HMGB1 inhibitors are likewise promising drug candidates for the treatment of patients suffering from COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abnormal response and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • abnormal response and adaptive innate: 1, 2
    • abnormal response and adaptive innate immunity: 1
    • abnormal response and lung disease: 1, 2, 3
    • abnormal response and lung injury: 1, 2, 3, 4
    • abnormal response and lymphocyte neutrophil: 1, 2
    • acid testing and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acid testing and admission time: 1, 2, 3, 4, 5
    • acid testing and lung disease: 1
    • acid testing and lung expression: 1
    • acid testing and lung injury: 1, 2, 3
    • acid testing and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acid testing and lymphocyte neutrophil: 1, 2, 3, 4
    • active ingredient and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active ingredient and admission time: 1, 2
    • active ingredient and lung disease: 1, 2
    • active ingredient and lung injury: 1, 2
    • activity expression and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
    • activity expression and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10